Redmile Group has raised $77.2 million to date for its Redmile Biopharma Investments I, according to a SEC filing. The San Francisco-headquartered firm has set a $150 million target and began fundraising in 2015. The SEC filing did not disclose whether the capital raise constituted a final or interim close.
The fund will target growth equity opportunities in biopharmaceutical sectors in North America.Â